ArticleCancer science2022

Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.

Yasuyuki Ikezawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.